

Reference:	FOI.17293.25
Subject:	Intravitreal injections or implants
Date of Request:	8 May 2025

Requested:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2025:

- Aflibercept
- Bevacizumab
- Brolocizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis
- Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2025:

Number of Injections/Implants: January to April 2025:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept			
Bevacizumab			
Dexamethasone			
Faricimab			
Ranibizumab - Lucentis			
Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)			

Response:

Hywel Dda University Health Board is unable to provide you with the exact number of cases due to the low number (less than 5). Where the figures in the tables below and overleaf have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of each of the listed intravitreal injections/implants administered, during the period 1 January to 30 April 2025.

Medication	Number
Aflibercept	645
Bevacizumab	0
Brolucizumab	0
Dexamethasone	136
Faricimab	1,452
Fluocinolone acetonide	*
Ranibizumab - Lucentis	22
Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	1,190

2. The UHB provides within the table below, the number of each of the listed intravitreal injections/implants administered, by eye condition, during the period 1 January to 30 April 2025.

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	359	117	169
Bevacizumab	0	0	0
Dexamethasone	*	65	70
Faricimab	1,035	203	214
Ranibizumab - Lucentis	14	6	*
Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	813	168	209